Replies to post #225299 on Biotech Values

[DewDiligence]

MRK withdraws Keytruda SCLC indication in US market—(a consequence of failure of the confirmatory study, KEYNOTE-604, to show a statsig OS benefit, as reported in Jan 2020):

https://finance.yahoo.com/news/merck-provides-keytruda-pembrolizumab-indication-210500073.html